Barclays analyst Matt Miksic says the discontinuation of the Acurate TAVR program at Boston Scientific (BSX) “should not come as a surprise to investors” given the failure to meet its non-inferiority endpoint last year. The firm views the news as “an incremental positive for the stock” as management will reallocate resources to innovative programs with greater potential for higher returns. The firm, which also notes that management reaffirmed its Q2 and 2025 outlook for reported, organic sales, and adjusted EPS, reiterates an Overweight rating and $125 price target on Boston Scientific shares.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific news ‘zero surprise,’ says JPMorgan
- Citi sees Boston Scientific stopping TAVR valve sales as ‘wise move’
- Boston Scientific’s Strategic Shift and Resilient Outlook: A Buy Rating with 17.7% Expected Return
- Boston Scientific’s Strategic Shift and Growth Potential: A Buy Rating Amid Product Discontinuation and Promising Innovations
- Boston Scientific discontinuing worldwide sales of ACURATE Aortic Valve Systems